We found that 35% (n = 4401/12 490) of cutaneous tumours tested positive for BRAF mutations, which was lower than reported in the existing literature (approximately 40%).8 Approximately half of patients with stage III/IV melanoma had a BRAF molecular test registered, suggesting inadequate testing over the study period. The gene discussed is BRAF; the disease is melanoma.